5 April 2018 EMA/525101/2014 Information Management

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide Insert of a Development Medicinal Product (DMP)

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Table of contents 1.1. DMP Example specification .................................................................................... 3 1.2. Create an XEVPRM ................................................................................................ 4 1.2.1. Type ................................................................................................................ 7 1.2.2. EV Code ........................................................................................................... 7 1.2.3. Sender Local Code ............................................................................................. 7 1.2.4. Sponsor ........................................................................................................... 8 1.2.5. Product Code .................................................................................................. 18 1.2.6. Product Name ................................................................................................. 19 1.2.7. Product Other Name ........................................................................................ 19 1.2.8. Comment ....................................................................................................... 20 1.2.9. Pharmaceutical Product .................................................................................... 20 1.2.10. Drug Routes .................................................................................................. 24 1.2.11. Drug Ingredients ........................................................................................... 27 1.2.12. Drug ATC ...................................................................................................... 61 1.2.13. Drug Indications ............................................................................................ 62 1.2.14. Product Attachments ...................................................................................... 66 1.3. Validate and send an XEVPRM .............................................................................. 77 1.4. Retrieve the XEVPRM Acknowledgement (XEVPRM ACK) .......................................... 80

All examples used in this step-by-step guide are fictitious and intended for demonstration purposes only.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 2/83

1.1. DMP Example specification For the purpose of this step-by-step exercise, the DMP should be inserted as per the below specifications: SPONSOR Labox High street Dublin DU12 5NN Ireland [email protected] PHARMACEUTICAL FORM AND METHOD OF ADMINISTRATION Capsule for oral use QUALITATIVE AND QUANTITATIVE COMPOSITION The drug to which the sponsor refers to as “MK005” is studied as a capsule for the treatment of low back pain and contains the following ingredients: •

100 mg of Paracetamol (active ingredient)



Up to 200 mg of "SubstanceB" , which is a newly developed chemical substance (active ingredient)



Orange flavour (excipient)



IB dated 20. August 2014

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 3/83

1.2. Create an XEVPRM 1) Log in to the requested EVWEB environment: EVWEB production:

https://eudravigilance.ema.europa.eu/x

XCOMP (test) environment:

https://evtest.ema.europa.eu/x

EVWEB training environment: https://eudravigilance-training.ema.europa.eu/x/

In the restricted area, click on "EVWEB":

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 4/83

You are now logged in EVWEB – the organisation ID under which you are logged in is shown in the top right corner:

2) Go to "Create and Send Product Reports" section:

3) With your mouse, click on the area next to the "Message Number". It is a free-text field. The area will become highlighted in blue:

4) Press "Enter" on your keyboard or click on the "E" ("Text Edit") button. Both actions will activate the field and allow you to write the name you wish to assign to you XEVPRM:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 5/83

5) Type in the message number you wish to assign to your XEVPRM, then press "Enter" on your keyboard:

6) Expand the tree-view area by clicking on the "+" sign (see screenshot above) and click on the "Products" section, or double click on "Products" in the active area:

7) Select "New Development Product " by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 6/83

The active area will display the fields relevant for a DMP entity:



The "Operation type" field displays "Insert (1)" as a default. It is not possible to assign a different operation type.



Mandatory fields that must be populated are highlighted with the text "Field is Mandatory" or "Field is Mandatory Optional". 

Please note that not all mandatory fields are highlighted this way (some fields are business rules dependent). Additional mandatory fields/fields that must contain specific value may be highlighted during the validation process (see section 1.3. Validate and send an XEVPRM).



When information is entered in the individual mandatory fields, the text "Field is Mandatory"/"Field is Mandatory Optional" disappears.



Some of the fields contain look-up tables with pre-defined values. These values will be displayed if you press "Enter" on your keyboard.

Enter the relevant information in the individual fields as per guidance provided for each field in the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) User Manual, section 3.2.2. Insert of a development medicinal product (DMP).

1.2.1. Type The value in the "Type" field is automatically set to "Development" as per your selection.

1.2.2. EV Code The EV Code field is a field which will automatically display the assigned EV Code if maintenance related operation (i.e. NOT an insert) is performed. In your example, this field is blank because you are performing an insert of an entity.

1.2.3. Sender Local Code "Sender Local Code" is a non-mandatory field. It is a free text field. Should you wish to assign your own local code for your internal reference, use the same process as described in steps 3 – 5.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 7/83

1.2.4. Sponsor The "Sponsor" field is a field that will allow you to search available values. Using your mouse, click on the area next to "Sponsor". The area will become highlighted in blue:

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button and the remote look-up search area becomes available:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 8/83

As per your example, the sponsor of your DMP is "Labox". You should therefore query the Sponsor organisation name for "Labox". You can also use one of the wild cards (*):

Enter the sponsor name in the search field and press "Enter" on your keyboard. If this sponsor organisation is available in the remote look-up list, the result will be displayed below the query area. In this case, the following message is displayed on your screen:

You can therefore presume that this sponsor organisation is not yet available in the XEVMPD. In order to reference this sponsor organisation in your DMP entity, you need to insert this sponsor organisation in the XEVMPD as new via the same XEVPRM through which you are submitting your DMP.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 9/83

Dismiss the displayed message by clicking on "OK". Using your mouse, click on the "Organisations" section in the tree-view area and select "New Sponsor" by ticking the relevant box in the active area:

The active area will display the fields relevant for a sponsor organisation entity:



The "Operation type" field displays "Insert (1)" as a default. It is not possible to assign a different operation type.



Mandatory fields that must be populated are highlighted with the text "Field is Mandatory". 

Please note that not all mandatory fields are highlighted this way (some fields are business rules dependent). Additional mandatory fields/fields that must contain specific value may be highlighted during the validation process (see section 1.3. Validate and send an XEVPRM).



When information is entered in the individual mandatory fields, the text "Field is Mandatory" disappears.



Some of the fields contain look-up tables with pre-defined values. These values will be displayed if you press "Enter" on your keyboard.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 10/83

1.2.4.1. EV Code The EV Code field is a field which will automatically display the assigned EV Code if maintenance related operation (i.e. NOT an insert) is performed. In your example, this field is blank because you are performing an insert of an entity. 1.2.4.2. Type The value in the "Type" field is automatically set to "Sponsor" as per your selection. 1.2.4.3. Sponsor Name It is mandatory to provide information in the Sponsor Name field. This is a free-text field. Using your mouse, click on the area next to "Sponsor Name". The area will become highlighted in blue:

Press "Enter" on your keyboard or use the "E" ("Text Edit") button. Both actions will activate the field and allow you to write your text:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 11/83

Type in the requested text and press "Enter" on your keyboard. The name of your sponsor will be displayed in the "Sponsor Name" field:

1.2.4.4. Sponsor Sender ID It is not mandatory to provide information in this field. This is a free text field. The organisation ID that corresponds to the same organisation as assigned in the EudraVigilance registration system may be provided. Should you wish to enter the organisation ID in this field, use the same process as described in section 1.2.4.3. Sponsor Name. 1.2.4.5. Address, City, Region and Postcode It is mandatory to provide information in the "Address", "City" and "Postcode" fields. It is not mandatory to provide information in the "Region" field. These are all free-text fields.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 12/83

To enter the requested information in these fields, use the same process as described in section 1.2.4.3. Sponsor Name:

1.2.4.6. Country Code It is mandatory to provide information in this field. The "Country Code" field is a field that will allow you to select one of the available pre-defined values. Using your mouse, click on the area next to "Country Code". The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 13/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

Using your mouse, select the requested value. It will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 14/83

Once you click on the selected value, it will be displayed in the "Country Code" field:

1.2.4.7. Tel Number, Extension, Country Code, Fax Number, Fax Extension, Fax Country Code and E-mail address It is not mandatory to provide information in these fields. These are free-text fields. Should you wish to enter the requested information in these fields, use the same process as described in section 1.2.4.3. Sponsor Name. 1.2.4.8. Comment This is a free- text field, in which information can be entered using the same process as described in section 1.2.4.3. Sponsor Name. As per the applicable business rules, the "Comment" field must contain the reason for nullification if operation type 'Nullification (4)' is used on the sponsor entity. No information should be entered in this field in this particular case since you are performing an 'Insert (1)' of an entity.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 15/83

You have now populated the fields for a sponsor organisation entity "Labox":

To reference the newly created sponsor organisation in your DMP entity, go back to your development medicinal product entry by clicking on "Insert (1) – Development" at the top of the tree-view area:

The active area will display the fields relevant for a DMP submission:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 16/83

Using your mouse, click on the area next to "Sponsor". The area will become highlighted in blue:

By clicking on the "L" (Local look-up") button, the field will become highlighted in grey and the available local look-up table becomes available, displaying the organisation name, which you inserted in the "Organisations" section of your XEVPRM:

Using your mouse, select the sponsor name you wish to reference in the "Sponsor" field. The name will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 17/83

Once you press "Enter" on your keyboard or click on the selected value with our mouse, the sponsor name will be displayed in the "Sponsor" field:

1.2.5. Product Code This is a free-text field. Using your mouse, click on the area next to "Product Code". The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 18/83

Press "Enter" on your keyboard or use the "E" ("Text Edit") button. Both actions will activate the field and allow you to write your text:

Type in the requested text and press "Enter" on your keyboard. The text will be displayed in the "Product Code" field:

1.2.6. Product Name This is a free-text field. As per guidance provided in section 3.2.2. Insert of a development medicinal product (DMP) of the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) User Manual, in our example, the "Product Name" field can be left blank or contain a name created as a concatenation of the substance code or name and concentration. Should you wish to assign an XEVMPD name to your DMP, use the same process as described in steps 3 – 5 of 1.2.4.3. Sponsor Name.

1.2.7. Product Other Name This is a free-text field. To enter information in this field, use the same process as described in steps 3 – 5 or section 1.2.4.3. Sponsor Name should be used.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 19/83

For our example, you will leave this field blank.

1.2.8. Comment This is a free- text field, in which information can be entered using the same process as described in steps 3 – 5 or section 1.2.4.3. Sponsor Name. As per the applicable business rules, the "Comment" field must contain the reason for nullification if operation type 'Nullification (4)' is used on the sponsor entity. No information should be entered in this field in this particular case since you are performing an 'Insert (1)' of an entity. You now need to provide information about the pharmaceutical product.

1.2.9. Pharmaceutical Product This is a repeatable section. Each medicinal product entry in the XEVMPD must contain at least one pharmaceutical product. The technical concept of a "pharmaceutical product" refers to the qualitative and quantitative composition of a medicinal product in the pharmaceutical form approved for administration. The "Administrable pharmaceutical form" refers to the pharmaceutical form for administration to the patient, after any necessary transformation of the authorised pharmaceutical form has been carried out. A medicinal product may contain one or more "pharmaceutical product". Click on the "Pharmaceutical Products" section in the tree-view area, or on "Pharmaceutical Products" in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 20/83

Select "New Pharmaceutical Product" by ticking the relevant box in the active area:

The active area will display the fields applicable for the (administrable) pharmaceutical product. The text next to "Administrable Pharmaceutical Form" is highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 21/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button and the remote look-up search area becomes available:

Type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed:



If the standard term of the requested administrable pharmaceutical form is available in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), such standard term should be used in the pharmaceutical product entity.



If the required pharmaceutical form is NOT available as a standard term but is available as a proposed term in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), such proposed term should be used in the pharmaceutical product entity.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 22/83



If the pharmaceutical form is not available as a standard or proposed term in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), and: o

where an application for a new pharmaceutical form was/will be submitted to the maintenance Organisation (i.e. EDQM) with the request of adding it to the standard term list; and

o

the requested pharmaceutical form is not included in the list of proposed pharmaceutical forms re-mapped to standard pharmaceutical forms in the spread sheet “Re-mapped_PDFs” published in the Controlled Vocabulary (CV) list "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms, available at the Agency's website;

the pharmaceutical form can be provided as a new proposed term via the XEVPRM. See section 1.8. Initial submission of an Authorised/Administrable Pharmaceutical Form of the published Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance for related guidance. 

If the Sponsor developed a new pharmaceutical form, which is confidential and it is used in a clinical trial, such term can be entered in the XEVMPD as a new development term. Development terms can only be used in Development Medicinal Products only. See section 1.8. Initial submission of an Authorised/Administrable Pharmaceutical Form of the published Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance for related guidance.

Select the requested value, double-click or press "Enter" on your keyboard. The selected value will be displayed in the "Administrable Pharmaceutical Form" field:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 23/83

1.2.10. Drug Routes This is a repeatable section. Administration route section describes the route(s) of administration i.e. the path by which the medicinal product (described as technical concept of a "pharmaceutical product") is taken into or makes contact with the body. Click on the "Drug Routes" section within the pharmaceutical product in the tree-view area, or on "Drug Routes" in the active area:

Select "New Drug Route" by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 24/83

The active area will display the field (highlighted in blue) in which the route of administration of the pharmaceutical product must be specified based on the available values:

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button and the remote look-up search area becomes available:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 25/83

Type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed:



If the standard term of the required route of administration is available in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), such standard term should be used in the pharmaceutical product entity.



If the required route of administration is NOT available as a standard term but is available as a proposed term in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), such proposed term should be used in the pharmaceutical product entity.



If the required route of administration is not available as a standard or proposed term in the Lookup table/Controlled Vocabulary (CV) list published on the Agency's website (see "eXtended Eudravigilance Product Dictionary (XEVMPD) pharmaceutical dose forms"), and: o

where an application for a new route of administration was/will be submitted to the maintenance Organisation (i.e. EDQM) with the request of adding it to the standard term list; and

o

the requested pharmaceutical form is not included in the list of proposed routes of administration re-mapped to standard routes of administration in the spread sheet “Re-mapped_RoAs” published in the Controlled Vocabulary (CV) list "eXtended Eudravigilance Product Dictionary (XEVMPD) routes of administration, available on the Agency's website;

the route of administration can be provided as a new proposed term via the XEVPRM. See section 1.9. Initial Submission of a Route of Administration (RoA) of the published Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance for related guidance. 

If the Sponsor developed a new route of administration, which is confidential and it is used in a clinical trial, such term can be entered in the XEVMPD as a new development term.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 26/83

Development terms can only be used in Development Medicinal Products only. See section 1.9. Initial Submission of a Route of Administration (RoA) of the published Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance for related guidance. Select the requested value, double-click or press "Enter" on your keyboard. The selected value will be displayed in the "Route of Administration" field:

You now need to provide information about the active ingredients of the pharmaceutical product.

1.2.11. Drug Ingredients This is a repeatable section. Each pharmaceutical product must contain information on the active ingredient(s), including the active ingredient substance name(s) and its/their concentration(s). It is not mandatory to provide information on excipients for development medicinal products.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 27/83

Click on "Drug Ingredients" within the "Pharmaceutical Products" section in the tree-view area:

Select "New Drug Ingredient" by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 28/83

The active area will display the fields applicable for the composition of the (administrable) pharmaceutical product:

1.2.11.1. Substance Name The substance(s) indicated as the active ingredient(s) of the medicinal product according to the clinical trial documentation must be specified. By clicking on the "Remote Lookup", the search area, where you can query values available for this field (i.e. substance names) will be displayed:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 29/83

Type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed:



If the requested approved substance is not available, please follow the process described in the published communication "Changes to some business rules of the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD): Submission of substance information".



If the requested substance is a new development substance, see section 1.2.11.4. Insert of a development substance.

Select the requested value, double-click or press "Enter" on your keyboard. The selected value will be displayed in the "Substance name" field:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 30/83

1.2.11.2. Role of Ingredient In the "Role of Ingredient" section, click on the applicable value:

You have now specified that the substance with the name "Paracetamol" is an active ingredient in our administrable pharmaceutical product:

1.2.11.3. Ingredient Strength Information Whenever possible, the substance strength should be expressed as a unit of measurement. Strength must be entered in the XEVMPD in accordance with the ISO IDMP standards based on a numerator and denominator. Strength can be therefore expressed in two ways: •

As a Unit of Measure: When the strength of a medicinal product described as a technical concept of a “Pharmaceutical Product” that has undergone a transformation (for example reconstitution) is to be specified, it is to be specified using the strength resulting from transformation undertaken exactly in accordance with the regulated product information. EXAMPLES of units of measure: 10 milligrams per 100 millilitres, 10 milligrams per 1 single day.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 31/83



As a unit a Presentation: The unit of presentation is a qualitative term describing the discrete unit in which a “pharmaceutical product” is presented to describe strength or quantity in cases where a quantitative unit of measurement is not appropriate. EXAMPLES of units of presentation: 250 milligrams per 1 single tablet, 10 millilitres per one single spoon. Unit of presentation can be expressed as: − Strength; e.g. spray/puff contains 100 mcg per actuation (unit of presentation = actuation); − Quantity; e.g. bottle contains 100 ml per bottle (unit of presentation = bottle).

Where an ingredient is present in the form of a salt or hydrate, the quantitative composition may be expressed in terms of the mass [or biological activity in International (or other) units where appropriate] of the active moiety (base, acid or anhydrous material). •

If the strength is declared as the amount of base then the base is the substance to be declared as the ingredient.



If the strength is declared as the amount of the salt then the salt is the substance to be declared as the ingredient.



In the rare examples where the strength of the salt and the base are both declared, then the salt is the substance to be declared as the ingredient. This is in line with IDMP where the both the substance (salt) and the reference substance (base/active moiety) will need to be defined. EXAMPLE of Reference substance/strength: "60 mg toremifene (as citrate)" or "toremifene citrate equivalent to 60 mg toremifene" – the substance 'toremifene' will be specified as the active ingredient in the pharmaceutical product.

Where the active ingredient is an ester or pro-drug, the quantitative composition may be stated in terms of the quantity of that ester or pro-drug.

The strength of the substance is to be specified as a quantity of the substance present in a medicinal product described as the technical concept of a "pharmaceutical product". The following concentration type values (amount value types) are available for use as part of the XEVMPD look-up table/Controlled Vocabulary (CV) lists published on the Agency's website (see Extended EudraVigilance product report message concentration types): • Equal (1) • Range (2) • Up to (3) • Not less than (4) • Approximately (5) • Average (6)

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 32/83

In the "Ingredient Strength Information" section, click on the applicable value:

You are prompted to select whether the concentration (of the active ingredient) should be expressed as "Units of Measure" or "Units of Presentation". As per our DMP example specification, the capsule contains 100 mg of Paracetamol (active ingredient) - you will enter the concentration of the active ingredient as "Units of Presentation".

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 33/83

Click on "Units of Presentation":

The numerator value is a free-text field. Type in the requested value:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 34/83

The numerator prefix is a look-up list containing pre-defined values. Click on the arrow and select the requested value:

The numerator prefix value is now displayed in the "Prefix" section:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 35/83

The numerator unit is a look-up list containing pre-defined values. Click on the arrow and select the requested value:

The numerator unit value is now displayed in the "Unit" section:

The denominator value is a free-text field. Type in the requested value:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 36/83

The denominator prefix is a look-up list containing pre-defined values. Click on the arrow and select the requested value:

The denominator prefix value is now displayed in the "Prefix" section:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 37/83

The denominator unit is a look-up list containing pre-defined values. Click on the arrow and select the requested value:

The denominator unit value is now displayed in the "Unit" section and you have now entered that one capsule contains 100 mg of the active substance paracetamol:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 38/83

Since our administrable pharmaceutical product contains not one but two active ingredients, you will also need to enter "SubstanceB" and its concentration (up to 200 mg) as another active ingredient. In the tree-view area, within the "Pharmaceutical Products" section, click on the text "Drug Ingredients":

The active are displays the previously entered substance name, its role and concentration. Select "New Drug Ingredient" by ticking the relevant box:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 39/83

The active area will display the fields applicable for the composition of the (administrable) pharmaceutical product:

By clicking on the "Remote Lookup", the search area, where you can query values available for this field (i.e. substance names) will be displayed:

Type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed. In this particular case, a warning message is displayed, informing us that "SubstanceB" cannot be retrieved in the available substance list:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 40/83

You can therefore presume that this substance name is not yet available in the XEVMPD. Dismiss the displayed message by clicking on "OK". In order to reference this substance name in your DMP entity, you need to insert this substance in the XEVMPD as new via the same XEVPRM through which you are submitting your DMP. Any substance under investigation in a clinical trial in the EEA, and which is not part of any authorised medicinal product (AMP) should be submitted as a new development substance. 1.2.11.4. Insert of a development substance Using your mouse, click on the "Substances" section in the tree-view area and select "New Development Substance" by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 41/83

The active area will display the fields relevant for a development substance entity:



The "Operation type" field displays "Insert (1)" as a default. It is not possible to assign a different operation type.



Mandatory fields that must be populated are highlighted with the text "Field is Mandatory". 

Please note that not all mandatory fields are highlighted this way (some fields are business rules dependent). Additional mandatory fields/fields that must contain specific value may be highlighted during the validation process (see section 1.3. Validate and send an XEVPRM).



When information is entered in the individual mandatory fields, the text "Field is Mandatory" disappears.



Some of the fields contain look-up tables with pre-defined values. These values will be displayed if you press "Enter" on your keyboard.

Enter the relevant information in the individual fields as per guidance provided for each field in the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) User Manual, section 3.2.4. Insert of a development substance. 1.2.11.4.1. Type The value in the "Type" field is automatically set to "Development" as per our selection.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 42/83

1.2.11.4.2. EV Code The EV Code field is a field which will automatically display the assigned EV Code if maintenance related operation (i.e. NOT an insert) is performed. In our example, this field is blank because you are performing an insert of an entity. 1.2.11.4.3. Current Name or Code This is a free-text field. Using your mouse, click on the area next to "Current Name or Code". The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 43/83

Press "Enter" on your keyboard or use the "E" ("Text Edit") button. Both actions will activate the field and allow you to write your text:

Type in the requested text and press "Enter" on your keyboard. The text will be displayed in the "Current Name or Code" field:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 44/83

1.2.11.4.4. Is Name or Code The "Is Name or Code" field is a field that will allow you to select one of the available pre-defined values. Using your mouse, click on the area next to "Is Name or Code”. The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 45/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

Using your mouse, select the requested value. It will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 46/83

Once you click on the selected value, it will be displayed in the "Is Name or Code" field:

1.2.11.4.5. Class The "Class" field is a field that will allow you to select one of the available pre-defined values. Using your mouse, click on the area next to "Class”. The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 47/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

Using your mouse, select the requested value. It will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 48/83

Once you click on the selected value, it will be displayed in the "Class" field:

1.2.11.4.6. Sponsor The "Sponsor" field is a field that will allow you to search available values. Using your mouse, click on the area next to "Sponsor”. The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 49/83

You already know that the sponsor organisation "Labox" was not inserted in the XEVMPD (and therefore no EVCode was assigned) and is therefore not available in the remote look-up list. You should therefore search the local look-up list by clicking on the "L" (Local look-up") button. The field will become highlighted in grey and the available local look-up table becomes available, displaying the organisation name, which you inserted in the "Organisations" section of your XEVPRM:

Using your mouse, select the sponsor name you wish to reference in the "Sponsor" field. The name will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 50/83

Once you press "Enter" on your keyboard or click on the selected value with our mouse, the sponsor name will be displayed in the "Sponsor" field:

1.2.11.4.7. CAS Number, Molecular Formula and Chemical/Biological Description These are free-text field. The requested information in these fields can be specified using the same process as described in steps 3 – 5 of section 1.2.4.3. Sponsor Name. In our example, you will leave these fields blank. 1.2.11.4.8. Comment This is a free- text field, in which information can be entered using the same process as described in steps 3 – 5 or section 1.2.4.3. Sponsor Name. As per the applicable business rules, the "Comment" field must contain the reason for nullification if operation type 'Nullification (4)' is used on the sponsor entity. No information should be entered in this field in this particular case since you are performing an 'Insert (1)' of an entity. 1.2.11.4.9. Previous Name/Codes (of the development substance) This is a repeatable section. Since no previous substance name/code is stated in the DMP example specification, this section should not contain any information.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 51/83

Should you wish to add the relevant information, click on "Previous Name/Codes" section in the treeview area, or on "Previous Name/Codes" in the active area:

Select "New" by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 52/83

The active area will display the fields applicable for the previous name or code. The text next to "Substance Name or Code" is highlighted in blue:

It is a free-text field. Should you wish to add the information, the same process as described in section 1.2.11.4.3. Current Name or Code should be followed. To specify whether the entered information is a name or a code, click on the area next to "Is Name or Code". It is a field that will allow you to select one of the available pre-defined values. The same process as described in section 1.2.11.4.4. Is Name or Code should be followed. 1.2.11.4.10. International Code This is a repeatable section. Since no international code is stated in the DMP example specification, this section should not contain any information. Should you wish to add the information, the same processes as described in section 1.2.11.4.9. Previous Name/Codes (of the development substance) should be followed. 1.2.11.4.11. Substance Parent Code This is a repeatable section. Since no substance parent code code is stated in the DMP example specification, this section should not contain any information. Should you wish to add the information, the same processes as described in section 1.2.11.4.9. Previous Name/Codes (of the development substance) should be followed. 1.2.11.4.12. Substance Attachment For development substances, attachments may be sent. Should you wish to add a substance attachment, follow the processes described in section 3.2.14.2. Insert of Printed Substance Information (PSI) of the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) User Manual. You have now populated the fields for a development substance "SubstanceB".

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 53/83

To reference the newly created substance in the pharmaceutical product of your DMP entity, go back to the "Drug Ingredient" section in the tree-view area and select "Drug Ingredient":

The active area will display the fields applicable for the composition of the (administrable) pharmaceutical product:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 54/83

Click on the "L" (Local look-up") button to display the available local look-up containing the substance name, which you inserted in the "Substances" section of your XEVPRM:

Using your mouse, select the substance name you wish to reference in the "Substance Name" field. The name will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 55/83

Once you press "Enter" on your keyboard or click on the selected value with our mouse, the substance name will be displayed in the "Substance Name" field:

To specify the role of the ingredient and the ingredient strength information, follow the same processes as described in sections 1.2.11.2. Role of Ingredient and 1.2.11.3. Ingredient Strength Information. Once completed, the information should be displayed as follows:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 56/83

The tree-view area now displays two substance names and their role under "Drug Ingredients":

If you click on the text "Drug Ingredients" in the tree-view area, the details of the two ingredients will be displayed in the active area:

To insert your third substance (i.e. orange flavour) as an excipient, click on "Drug Ingredients" within the "Pharmaceutical Products" section in the tree-view area and select "New Drug Ingredient" by ticking the relevant box in the active area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 57/83

The active area will display the fields applicable for the composition of the (administrable) pharmaceutical product:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 58/83

Click on the "Remote Lookup" and the search area, where you can query values available for this field (i.e. substance names) will be displayed:

Type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 59/83



If the requested approved substance is not available, please follow the process described in the published communication "Changes to some business rules of the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD): Submission of substance information".



If the requested substance is a new development substance, see section 1.2.11.4. Insert of a development substance.

Select the requested value, double-click or press "Enter" on your keyboard. The selected value will be displayed in the "Substance name" field:

To indicate that "Orange flavour" is an excipient, click on "Excipient" in the "Role of Ingredient" section:

It is not mandatory to enter the concentration of excipients.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 60/83

The tree-view area now displays three substance names and their role under "Drug Ingredients":

If you click on the text "Drug Ingredients" in the tree-view area, the details of the three ingredients will be displayed in the active area:

1.2.12. Drug ATC This is a repeatable section. It is not mandatory to provide ATC Code information in a DMP entity. Should you wish to do so, the same process as described in section 1.2.10. Drug Routes should be followed.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 61/83



If the standard term of the requested ATC Code is available in the Lookup table, such standard term should be used in the pharmaceutical product entity.



If the required ATC Code is NOT available as a standard term but it is available as a proposed term in the Lookup table, such proposed term should be used in the pharmaceutical product entity.



If the Sponsor created a new ATC Code, which is confidential, such term can be entered in the XEVMPD as a new development term. Development terms can be used in Development Medicinal Products only. See section 1.7. Initial submission of an ATC Code of the published Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance for related guidance.

1.2.13. Drug Indications This is a repeatable section. It is not mandatory to provide Drug Indications information in a DMP entity. Should you wish to do so, the below described process should be followed. The information in the "Drug Indications" section should be entered as per business rules and guidance provided in Chapter 3.II: Extended EudraVigilance product report message (XEVPRM) user guidance; section 1.2.19. AMP - Product Indications (AP.INDs). Click on the "Drug Indications" text in the tree-view area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 62/83

Select "New Drug Indication" by ticking the relevant box in the active area:

The active area will display the fields applicable for MedDRA coding:

1.2.13.1.1. MedDRA Version The area next to the "MedDRA Version" is highlighted in blue:

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 63/83

Using your mouse, select the requested value. It will become highlighted in black:

Once you click on the selected value, it will be displayed in the "MedDRA Version" field:

1.2.13.1.2. MedDRA Level Click on the area next to the "MedDRA Level". The area will become highlighted in blue:

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 64/83

Using your mouse, select the requested value. It will become highlighted in black:

Once you click on the selected value, it will be displayed in the "MedDRA Level" field:

1.2.13.1.3. MedDRA Term Click on the area next to the "MedDRA Term". The area will become highlighted in blue:

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button and the remote look-up search area becomes available:

Select your query mode and type in the requested value (you can also use some of the wild cards) and press "Enter". The list of available values will be displayed:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 65/83

Select the requested value, double-click or press "Enter" on your keyboard. The selected value will be displayed in the "MedDRA Term" field:

To enter additional drug indications, click on "Drug Indications" in the tree-view area and select "New Drug Indication". The same process as described in section 1.2.13. Drug Indications should be followed.

1.2.14. Product Attachments This is a repeatable section. It is not mandatory to provide Product Attachments in a DMP entity. Should you wish to do so, the below described process should be followed to attach the Investigator's Brochure or other clinical trial documentation: Click on the "Product attachments" text in the tree-view area:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 66/83

Select "New Product Attachment" by ticking the relevant box in the active area:

The area next to "Product Attachment" is highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 67/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button and the remote look-up search area becomes available:

As per your example, the code of the medicinal product is "MK005". You should therefore search for a document name that contains part of this code. You can also use one of the available wild cards. Type in the requested text and press "Enter" on your keyboard. If document containing such text was previously submitted to the XEVMPD (and an EV Code was assigned), a result of your search would be displayed in the search area. In this case, the following message is displayed on your screen:

You can therefore presume that a document for such medicinal product was not previously inserted in the XEVMPD and can therefore be inserted as new.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 68/83

In the tree-view are, click on the "Attachments" section:

Select "New PPI Attachment" by ticking the relevant box in the active area:

The active area will display the fields applicable for a PPI attachment. Enter the relevant information in the individual fields as per the below guidance: 1.2.14.1.1. File type The "File Type" field is a field that will allow you to select one of the available pre-defined values. "PDF (1)" will be automatically assigned and highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 69/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The other values available for this field will be displayed:

Using your mouse, select the requested value. It will become highlighted in black:

Once you click on the selected value, it will be displayed in the "File Type" field:

1.2.14.1.2. Name This is a free-text field. Using your mouse, click on the area next to "Name". The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 70/83

Press "Enter" on your keyboard or use the "E" ("Text Edit") button. Both actions will activate the field and allow you to write your text:

Type in the requested text and press "Enter" on your keyboard. The name of your attachment will be displayed in the "Name" field:

1.2.14.1.3. Type The type of your attachment is automatically assigned as per your earlier indication:

1.2.14.1.4. Language The "Language" field is a field that will allow you to select one of the available pre-defined values. Using your mouse, click on the area next to "Language”. The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 71/83

Press "Enter" on your keyboard, double-click on the field, or click on the "R" (Remote look-up) button. The values available for this field will be displayed:

Using your mouse, select the requested value. It will become highlighted in black:

Once you click on the selected value, it will be displayed in the "Language" field:

1.2.14.1.5. Version number This is a free-text field. Using your mouse, click on the area next to "Version Number". The area will become highlighted in blue:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 72/83

Press "Enter" on your keyboard or use the "E" ("Text Edit") button. Both actions will activate the field and allow you to write your text:

Type in the requested text and press "Enter" on your keyboard. The version number will be displayed in the "Version Number" field:

1.2.14.1.6. Version Date The "Version Date" field is a graphical interface that recalls a calendar, which allows you to select the requested date. Using your mouse, click on the area next to "Version Date". The area will become highlighted in blue:

Press "Enter" on your keyboard or double-click with your mouse. A calendar will be displayed. Using the relevant arrows, select the requested date:

Once you click on the requested date, the date will be displayed in the field:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 73/83

You have entered information for all fields required for the submission of a PPI attachment. To reference the newly created PPI attachment in your DMP entity, go back to your development medicinal product entity by clicking on the "Product Attachment" in the "Product Attachments" section in the tree-view area (highlighted in red):

The active area will display the fields relevant for an attachment submission.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 74/83

1.2.14.1.7. Product Attachment The area next to "Product Attachment" is highlighted in blue:

Click on the "L" (Local look-up") button - the area will become highlighted in grey and the local look-up table becomes available, displaying the attachment, which you inserted in the "Attachments" section of your XEVPRM:

Using your mouse, select the attachment name you wish to reference in the "Product Attachment" field. The name will become highlighted in black:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 75/83

Once you press "Enter" on your keyboard or click on the selected value with your mouse, the attachment name will be displayed in the "Product Attachment" field:

1.2.14.1.8. Validity declaration Since we are performing an insert of a DMP and no previous attachment was referenced to this DMP entity, it is not necessary to enter the "Validity declaration" information in this particular case. You have now completed all fields requested for a DMP submission as per the DMP example specification.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 76/83

1.3. Validate and send an XEVPRM 1) Validate your XEVPRM by clicking with your mouse on the "Validate" button.

A new window will be displayed on your screen, showing the result of your validation.



If your XEVPRM contains any technical errors (i.e. mandatory information is missing), an error message will be displayed on your screen, describing the number of errors and specifying the location of the first error:

Once you click on "OK" in the error message the application will direct you to the first error. The field(s) where information is missing will contain the text "Field is Mandatory", e.g.:

You should enter the required information /correct the submitted information and validate the XEVPRM again.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 77/83

If your XEVPRM has been created correctly, the new window will display the text "Validate OK", which mans that no errors were reported:

You can dismiss the message by clicking on "OK". 2) Save the XEVPRM for your reference by clicking on the relevant button:

3) Send the XEVPRM by clicking on the "Send" button. 

The below message will be displayed on your screen if you included a submission of a PPI attachment for your development product:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 78/83

Retrieve your PPI attachment from the location on your computer and upload the file:

Once you click on "Upload File", the following message will be displayed in a new window:

Dismiss the message by clicking on "OK". The below message will confirm that your XEVPRM has been sent:

If you want to view/save your file, click on "OK". The below message will be displayed, enabling you to save your XEVPRM file on your computer:

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 79/83

1.4. Retrieve the XEVPRM Acknowledgement (XEVPRM ACK) 1) Go to the "Web Trader" section

2) Click on "Inbox" (or "Archived Inbox" under "Archive", depending on when you decide to retrieve your XEVPRM ACK). The application will appear "frozen" for a second or two:

After a few seconds, the active area will display XEVPRM ACKs sent to your organisation's ID (the first message will be automatically highlighted in blue):

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 80/83

To view the ACK name in full, expand the section by placing your cursor on the separator line between "Name" and "Num/Count", click and drag towards the right until the full name is visible:

3) Based on the XEVPRM number, which you assigned to your message find the XEVPRM ACK. Click on the relevant row with your mouse (the message will be highlighted in blue):

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 81/83

Press "Enter" on your keyboard or double-click with your mouse and the XML of the XEVPRM ACK will be displayed on your screen, showing the operation result and the assigned EVCode(s):

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 82/83

4) You can save the XML file of the XEVPRM ACK on your computer by going to "File" and selecting "Save As":

You have now successfully retrieved the XEVPRM Acknowledgement.

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide EMA/525101/2014

Page 83/83

eXtended EudraVigilance Medicinal Product Report Message ...

eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step. Guide. EMA/525101/2014. Page 5/83. You are now logged in EVWEB – the organisation ID under which you are logged in is shown in the top right corner: 2) Go to "Create and Send Product Reports" section: 3) With your mouse, click ...

4MB Sizes 0 Downloads 54 Views

Recommend Documents

eXtended EudraVigilance Medicinal Product Report Message ...
1) Log in to the requested EVWEB environment: EVWEB ...... 4) You can save the XML file of the XEVPRM ACK on your computer by going to "File" and selecting.

eXtended EudraVigilance Medicinal Product Report Message ...
eXtended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step guide. EMA/543104/2014. Page 3/20. 1.1. Example specifications.

eXtended EudraVigilance Medicinal Product Report Message ...
Apr 5, 2018 - 1) Log in to the requested EVWEB environment: ...... on your keyboard or double-click with your mouse and the XML of the XEVPRM ACK.

eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD ...
43 Winston Road. London. E14 5EU. UK. [email protected] A sponsor organisation with the details: EraLab. Lockington Close. Margate. MA12 4JJ. UK.

Agenda and registration form - eXtended EudraVigilance Medicinal ...
Signature. ATTENDEE DETAILS: Cancellation Policy. All cancellations must be made in writing and be ... and/or digital camera, to be used by DIA in promotional.

Agenda and registration form - eXtended EudraVigilance medicinal ...
Bank transfers: When DIA completes your registration, an email will be ... complete the bank transfer. Payments in EURO ... 4051 Basel, Switzerland Web: www.

Post-orphan medicinal product designation procedures: guidance
Jul 12, 2017 - page 6. - Information relating to Brexit under heading 9 added on ..... grounds that the paediatric indication brought a significant clinical benefit in comparison with existing ..... European Union, plus Icelandic and Norwegian.

Medicinal product with a textile component
Jan 28, 2000 - Foreign Application Priority Data. Feb. 4, 1999. (EP) . ... medical products such as wound compresses consist for example of woven fabric,.

EudraVigilance auditable requirement project -EudraVigilance ...
Jun 23, 2017 - Send a question via our website www.ema.europa.eu/contact ..... Guide to support users of the EVWEB application. NCAs, MAHs, ... developers.

EudraVigilance User Manual - Individual Case Safety Report form
Jan 22, 2018 - field in the form will be left blank. This to avoid the population of forms non-medically confirmed at case level when at least one reporter is a HCP. 3.6. Patient. This table contains information about the patient concerned in the cas

2017 Annual Report on EudraVigilance for the European Parliament ...
Mar 15, 2018 - 7 http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/03/WC500222351.pdf. 8 Alvarez Y et al. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a r

Non-animal approaches in support of medicinal product development ...
Oct 5, 2017 - Non-animal approaches in support of ... Cardiovascular toxicity >>> CNS, lung, adapative immune system ... for regulatory decision making.

Watertown Extended Day Report FINAL (1).pdf
Program Site Coordinator at the J.R. Lowell School. Page 3 of 86. Watertown Extended Day Report FINAL (1).pdf. Watertown Extended Day Report FINAL (1).

Monthly statistics report: May 2016: medicinal products for human use ...
Jun 22, 2016 - Information Management Division. Monthly ... This document provides current information related to the volume and evaluation of marketing.